Arginase 1


Journal

Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549

Informations de publication

Date de publication:
06 2021
Historique:
revised: 11 01 2021
received: 20 10 2020
accepted: 28 01 2021
pubmed: 3 2 2021
medline: 23 3 2022
entrez: 2 2 2021
Statut: ppublish

Résumé

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which are characterized by their capability to suppress T-cell responses. While MDSCs have been traditionally associated with cancer diseases, their role as regulators of autoimmune diseases is emerging. Pemphigus is a chronic autoimmune blistering skin disease characterized by dysregulated T-cell responses and autoantibody production. The role of MDSCs in pemphigus disease has not been defined yet. The aim of this study was to characterize MDSCs in pemphigus patients and to dissect their relationship with CD4

Identifiants

pubmed: 33528891
doi: 10.1111/exd.14298
doi:

Substances chimiques

Arginase EC 3.5.3.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

782-791

Informations de copyright

© 2021 The Authors. Experimental Dermatology published by John Wiley & Sons.

Références

Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65(8):3044-3048.
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.
Wang Y, Schafer CC, Hough KP, et al. Myeloid-derived suppressor cells impair B cell responses in lung cancer through IL-7 and STAT5. J Immunol. 2018;201(1):278-295.
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268.
Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.
Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91(1):167-181.
Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233-4244.
Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4):1568-1573.
Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61(12):4756-4760.
Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123-1131.
Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 2011;117(24):6532-6541.
Lelis FJN, Jaufmann J, Singh A, et al. Myeloid-derived suppressor cells modulate B-cell responses. Immunol Lett. 2017;188:108-115.
Jaufmann J, Lelis FJN, Teschner AC, et al. Human monocytic myeloid-derived suppressor cells impair B-cell phenotype and function in vitro. Eur J Immunol. 2020;50(1):33-47.
Park MJ, Lee SH, Kim EK, et al. Myeloid-derived suppressor cells induce the expansion of regulatory B cells and ameliorate autoimmunity in the sanroque mouse model of systemic lupus erythematosus. Arthritis Rheumatol. 2016;68(11):2717-2727.
Wu H, Zhen Y, Ma Z, et al. Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci. Transl. Med.. 2016;8(331):331ra340.
Kurko J, Vida A, Glant TT, et al. Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disord. 2014;15:281.
Guo C, Hu F, Yi H, et al. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann Rheum Dis. 2016;75(1):278-285.
Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882-894.
Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67(5):869-877.
Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999;40(2 Pt 1):167-170.
Mindorf S, Dettmann IM, Krüger S, et al. Routine detection of serum antidesmocollin autoantibodies is only useful in patients with atypical pemphigus. Exp Dermatol. 2017;26(12):1267-1270.
Lotti R, Atene CG, Marconi A, et al. Development of a desmocollin-3 active mouse model recapitulating human atypical pemphigus. Front Immunol.. 2019;10:1387.
Ishii N, Teye K, Fukuda S, et al. Anti-desmocollin autoantibodies in nonclassical pemphigus. Br J Dermatol. 2015;173(1):59-68.
Solimani F, Maglie R, Pollmann R, et al. Thymoma-associated paraneoplastic autoimmune multiorgan syndrome-from pemphigus to lichenoid dermatitis. Front Immunol.. 2019;10:1413.
Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006;116(5):1159-1166.
Holstein J, Solimani F, Baum C, et al. Immunophenotyping in pemphigus reveals a T(H)17/T(FH)17 cell-dominated immune response promoting desmoglein1/3-specific autoantibody production. J Allergy Clin Immunol. 2020;S0091-6749(20):31624-31629.
Rizzo C, Fotino M, Zhang Y, Chow S, Spizuoco A, Sinha AA. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin Exp Dermatol. 2005;30(5):535-540.
Eming R, Budinger L, Riechers R, et al. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay. Br J Dermatol. 2000;143(6):1279-1282.
Veldman C, Höhne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol. 2004;172(10):6468-6475.
Yuan H, Zhou S, Liu Z, et al. Pivotal role of lesional and perilesional T/B lymphocytes in pemphigus pathogenesis. J Invest Dermatol. 2017;137(11):2362-2370.
Kim AR, Han D, Choi JY, et al. Targeting inducible costimulator expressed on CXCR5(+)PD-1(+) T(H) cells suppresses the progression of pemphigus vulgaris. J Allergy Clin Immunol. 2020;146(5):1070-1079.e8.
Stoll H, Ost M, Singh A, et al. Staphylococcal enterotoxins dose-dependently modulate the generation of myeloid-derived suppressor cells. Front Cell Infect Microbiol. 2018;8:321.
Schmidt E, Dahnrich C, Rosemann A, et al. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol. 2010;19(5):458-463.
Boulard C, Duvert Lehembre S, Picard-Dahan C, et al. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol. 2016;175(1):142-149.
Mahnke YD, Beddall MH, Roederer M. OMIP-017: human CD4(+) helper T-cell subsets including follicular helper cells. Cytometry A. 2013;83(5):439-440.
de St F, Groth B, Zhu E, Asad S, Lee L. Flow cytometric detection of human regulatory T cells. Methods Mole Biol. 2011;707:263-279.
Romano A, Parrinello NL, La Cava P, et al. PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy. Expert Rev Mol Diagn. 2018;18(7):675-683.
Nagaraj S, Youn J-I, Gabrilovich DI. Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol. 2013;191(1):17-23.
Oktem A, Horzum U, Ertop P, et al. Clinical relevance of polymorphonuclear myeloid-derived suppressor cells in autoimmune-blistering disorders pemphigus vulgaris and bullous pemphigoid. J Invest Dermatol. 2020.
Eming R, Hennerici T, Backlund J, et al. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells. J Immunol. 2014;193(9):4391-4399.
Hennerici T, Pollmann R, Schmidt T, et al. Increased frequency of T follicular helper cells and elevated interleukin-27 plasma levels in patients with pemphigus. PLoS One. 2016;11(2):e0148919.
Meier K, Holstein J, Solimani F, Waschke J, Ghoreschi K. Case report: apremilast for therapy-resistant pemphigus vulgaris. Front Immunol.. 2020;11:588315.
Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13):5439-5449.
MacDonald KP, Rowe V, Clouston AD, et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol. 2005;174(4):1841-1850.
Brys L, Beschin A, Raes G, et al. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol. 2005;174(10):6095-6104.
Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 2010;116(25):5738-5747.
Messmann JJ, Reisser T, Leithäuser F, Lutz MB, Debatin KM, Strauss G. In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity. Blood. 2015;126(9):1138-1148.
Chatterjee S, Das S, Chakraborty P, Manna A, Chatterjee M, Choudhuri SK. Myeloid derived suppressor cells (MDSCs) can induce the generation of Th17 response from naïve CD4+ T cells. Immunobiology. 2013;218(5):718-724.
Zhang H, Wang S, Huang Y, et al. Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation. Clin Immunol. 2015;157(2):175-186.
Zhang L, Zhang Z, Zhang H, Wu M, Wang Y. Myeloid-derived suppressor cells protect mouse models from autoimmune arthritis via controlling inflammatory response. Inflammation. 2014;37(3):670-677.
Yi H, Guo C, Yu X, Zuo D, Wang XY. Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J Immunol. 2012;189(9):4295-4304.
Casacuberta-Serra S, Costa C, Eixarch H, et al. Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis. Exp Neurol. 2016;286:50-60.

Auteurs

Davide Neri (D)

Molecular Immunology Charité (MIC), Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin, and Berlin Institute of Health, Berlin, Germany.
Department of Pediatrics 1, Medical Center Tübingen, Eberhard Karls University, Tübingen, Germany.

Melanie Carevic-Neri (M)

Molecular Immunology Charité (MIC), Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin, and Berlin Institute of Health, Berlin, Germany.

Jürgen Brück (J)

Department of Dermatology, Medical Center Tübingen, Eberhard Karls University, Tübingen, Germany.

Julia Holstein (J)

Department of Dermatology, Medical Center Tübingen, Eberhard Karls University, Tübingen, Germany.

Iris Schäfer (I)

Department of Dermatology, Medical Center Tübingen, Eberhard Karls University, Tübingen, Germany.

Farzan Solimani (F)

Molecular Immunology Charité (MIC), Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin, and Berlin Institute of Health, Berlin, Germany.

Rupert Handgretinger (R)

Department of Pediatrics 1, Medical Center Tübingen, Eberhard Karls University, Tübingen, Germany.

Dominik Hartl (D)

Department of Pediatrics 1, Medical Center Tübingen, Eberhard Karls University, Tübingen, Germany.
Novartis Institutes for Biomedical Research, Basel, Switzerland.

Kamran Ghoreschi (K)

Molecular Immunology Charité (MIC), Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin, and Berlin Institute of Health, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH